Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company engaged in inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. The Company's pipeline is focused on treating pulmonary fibrosis. It has three approved oral antifibrotic therapies for pulmonary fibrosis: pirfenidone; nintedanib, and nerandomilast. Its clinically advanced candidates, AP01 and AP02, are inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis, respectively. It has completed ATLAS, a Phase Ib clinical trial of AP01 in patients with IPF. AP02 is being evaluated in AURA, a global Phase II clinical trial for the treatment of IPF. It is also advancing AP03 into a Phase I clinical trial. AP03 is a fixed-dose combination of inhaled pirfenidone, and nintedanib designed to deliver dual antifibrotic mechanisms with the potential for additive or synergistic benefit.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļ- -
āļāļ·āđāļāļāļĢāļīāļĐāļąāļ- -
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļ- -
āļāļĩāļāļĩāđāļ- -
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ- -
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒ- -
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļ- -
āļāļĩāđāļāļĒāļđāđ- -
āđāļĄāļ·āļāļ- -
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđ- -
āļāļĢāļ°āđāļāļĻ- -
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ- -
āđāļāļĢāļĻāļąāļāļāđ- -
āđāļ§āđāļāđāļāļāđ- -
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļ- -
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļ- -
āļāļĩāļāļĩāđāļ- -
Dr. Ketan Patel, M.D.
Independent Director
Ms. Lyn Baranowski
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Ms. Heather D. Turner, J.D.
Ms. Heather D. Turner, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
Mr. Douglas (Doug) Carlson
Mr. Douglas (Doug) Carlson
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
Dr. Melissa Rhodes, Ph.D.
Dr. Melissa Rhodes, Ph.D.
Chief Operating Officer
Mr. Howard M. Lazarus, M.D.
Mr. Howard M. Lazarus, M.D.
Chief Medical Officer
Dr. Tiba Aynechi, Ph.D.
Independent Director
Ms. Jill Carroll
Independent Director
Mr. Jon Congleton
Independent Director
Dr. David Friedman, M.D.
Independent Director
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Dr. Ketan Patel, M.D.
Independent Director
Ms. Lyn Baranowski
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Ms. Heather D. Turner, J.D.
Ms. Heather D. Turner, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
Mr. Douglas (Doug) Carlson
Mr. Douglas (Doug) Carlson
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
Dr. Melissa Rhodes, Ph.D.
Dr. Melissa Rhodes, Ph.D.
Chief Operating Officer
Mr. Howard M. Lazarus, M.D.
Mr. Howard M. Lazarus, M.D.
Chief Medical Officer